|
REPL | Replimune Group, Inc. |
|
|
REPL | Replimune Group, Inc. |
| Biological Products (no Diagnostic Substances) |
| Book value per $ invested | $ 0.12 |
| Leverage | 58.15% |
| Market Cap | $ 862.5m |
| PE | 0.00 |
| Dividend Yield | 0.00% |
| Profit | $ -296.2m |
| Margin | 13308.66% |
Replimune Group, Inc., a biotechnology company, develops oncolytic immunogenic therapies to treat cancer. The company is headquartered in Woburn, Massachusetts.